Last Updated on March 2, 2022 by GlobeNewsWire
DALLAS, March 02, 2022 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will be participating in a Cell Therapy Panel at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 9:10 a.m. ET.
A live webcast of the presentation may be accessed at: https://wsw.com/webcast/cowen108/panel20/2319930 or by visiting the News & Events section of the Instil Bio website at http://www.instilbio.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.
About Instil Bio
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit http://www.instilbio.com and LinkedIn.
Contacts:
Media Contact:
1-833-446-7845 Ext. 1009
mediarelations@instilbio.com
Brendan Payne
Stern Investor Relations
1-212-362-1200
brendan.payne@sternir.com
